Crizotinib. ALK/Met inhibitor, oncolytic

Drugs of the Future

Volumn 36, Issue 2, 2011, Pages 91-98

  Nwizu, T ^a   Kanteti, R ^a   Kawada, I ^a   Rolle, C ^a   Vokes, E E ^a   Salgia, R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACOMITINIB; DOCETAXEL; DOXORUBICIN; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; ERLOTINIB; GEFITINIB; IMATINIB; MEMBRANE PROTEIN; PEMETREXED; PREDNISONE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 2P; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); COLOR; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA CELL; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SOLID TUMOR; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE;

EID: 84952979227     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.02.1584112     Document Type: Review

References (44)

1. Cui, J.J., Funk, L.A., Jia, L. et al. (Pfizer, Inc.; Agouron Pharmaceuticals, Inc.). Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. EP 1786785, JP 2008510790, US 2006046991, WO 2006021884.
2. Cui, J.J., Funk, L.A., Jia, L. et al. (Pfizer, Inc.). Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors. EP 1784396, JP 2008510788, WO 2006021881.
3. th ACS Natl Meet (April 6-10, New Orleans) 2008, Abst MEDI 105.
4. Blume-Jensen, P., Hunter, T. Oncogenic kinase signalling. Nature 2001, 411(6835): 355-65.
5. Baselga, J. Targeting tyrosine kinases in cancer: The second wave. Science 2006, 312(5777): 1175-8.
6. Soda, M., Choi, Y.L., Enomoto, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153): 561-6.
7. Soda, M., Takada, S., Takeuchi, K. et al. A mouse model for EML4-ALKpositive lung cancer. Proc Natl Acad Sci U S A 2008, 105(50): 19893-7.
8. Choi, Y.L., Takeuchi, K., Soda, M. et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68(13): 4971-6.
9. Takeuchi, K., Choi, Y.L., Togashi, Y. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15(9): 3143-9.
10. Rikova, K., Guo, A., Zeng, Q. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131(6): 1190-203.
11. Wong, D.W., Leung, E.L., So, K.K. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115(8): 1723-33.
12. Takahashi, T., Sonobe, M., Kobayashi, M. et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010, 17(3): 889-97.
13. Inamura, K., Takeuchi, K., Togashi, Y. et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3(1): 13-7.
14. Sakairi, Y., Nakajima, T., Yasufuku, K. et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010, 16(20): 4938-45.
15. Rodig, S.J., Mino-Kenudson, M., Dacic, S. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15(16): 5216-23.
16. Drexler, H.G., Gignac, S.M., von Wasielewski, R., Werner, M., Dirks, W.G. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000, 14(9): 1533-59.
17. Griffin, C.A., Hawkins, A.L., Dvorak, C., Henkle, C., Ellingham, T., Perlman, E.J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999, 59(12): 2776-80.
18. Coffin, C.M., Patel, A., Perkins, S., Elenitoba-Johnson, K.S., Perlman, E., Griffin, C.A. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001, 14(6): 569-76.
19. Cataldo, K.A., Jalal, S.M., Law, M.E. et al. Detection of t(2;5) in anaplastic large cell lymphoma: Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol 1999, 23(11): 1386-92.
20. Martelli, M.P., Sozzi, G., Hernandez, L. et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009, 174(2): 661-70.
21. Bottaro, D.P., Rubin, J.S., Faletto, D.L. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251(4995): 802-4.
22. Cipriani, N.A., Abidoye, O.O., Vokes, E., Salgia, R. MET as a target for treatment of chest tumors. Lung Cancer 2009, 63(2): 169-79.
23. Stamos, J., Lazarus, R.A., Yao, X., Kirchhofer, D., Wiesmann, C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 2004, 23(12): 2325-35.
24. Krishnaswamy, S., Kanteti, R., Duke-Cohan, J.S. et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009, 15(18): 5714-23.
25. Di Renzo, M.F., Narsimhan, R.P., Olivero, M. et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991, 6(11): 1997-2003.
26. Okuda, K., Sasaki, H., Yakiue, H., Yano, M., Fujii, Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008, 99(11): 2280-5.
27. Ma, P.C., Jagadeeswaran, R., Jagadeesh, S. et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65(4): 1479-88.
28. Maulik, G., Kijima, T., Ma, P.C. et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002, 8(2): 620-7.
29. Schmidt, L., Duh, F.M., Chen, F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16(1): 68-73.
30. Lee, J.H., Han, S.U., Cho, H. et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19(43): 4947-53.
31. Park, W.S., Dong, S.M., Kim, S.Y. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999, 59(2): 307-10.
32. Di Renzo, M.F., Olivero, M., Martone, T. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19(12): 1547-55.
33. Engelman, J.A., Zejnullahu, K., Mitsudomi, T. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827): 1039-43.
34. Gu, T.L., Deng, X., Huang, F. et al. Survery of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011, 6(1): e15640.
35. Christensen, J.G., Schreck, R., Burrows, J. et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003, 63(21): 7345-55.
36. Zou, H.Y., Li, Q., Lee, J.H. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67(9): 4408-17.
37. Christensen, J.G., Zou, H.Y., Arango, M.E. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6(12, Pt. 1): 3314-22.
38. Kwak, E.L., Bang, Y.J., Camidge, D.R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18): 1693-703.
39. Ou, S.H., Bazhenova, L., Camidge, D.R. et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010, 5(12): 2044-6.
40. Gambacorti-Passerini, C., Messa, C., Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011, 364(8): 775-6.
41. Butrynski, J.E., D'Adamo, D.R., Hornick, J.L. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010, 363(18): 1727-33.
42. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., Sawyers, C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2):117-25.
43. Hammerman, P.S., Jänne, P.A., Johnson, B.E. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009, 15(24): 7502-9.
44. Choi, Y.L., Soda, M., Yamashita, Y. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363(18):1734-9.